Please login to the form below

Not currently logged in

CGRP antagonists

This page shows the latest CGRP antagonists news and features for those working in and with pharma, biotech and healthcare.

Teva buys into Heptares oral CGRP programme for migraine

Teva buys into Heptares oral CGRP programme for migraine

The agreement - which includes a $10m upfront payment from Teva to Heptares - covers a series of small-molecule calcitonin gene-related peptide (CGRP) antagonists, all of which are currently in preclinical ... CGRP is a neurotransmitter that is elevated

Latest news

  • Allergan stumps up $375m for bolt-on acquisitions Allergan stumps up $375m for bolt-on acquisitions

    The deal with Merck covers MK-1602 and MK-8031, both of which are orally active, small molecule CGRP antagonists for the acute treatment of migraines. ... They are in a race to market with other CGRP antagonists such as Teva's TEV-48125 - which is also

  • Migraine drugs' headache Migraine drugs' headache

    CGRP can also cause the release of inflammatory agents from meningeal mast cells. ... It is thought that CGRP receptor antagonists could alleviate migraine symptoms by blocking these pathophysiological activities of CGRP.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...